1∶chiesae，binit，adornif，capettia，rizzardinig，faggioni(编辑修改稿)

1∶chiesae，binit，adornif，capettia，rizzardinig，faggioni(编辑修改稿)内容摘要：

J Virol. 2020 Nov。 76(21):1110412. PMID: 12368352 [PubMed indexed for MEDLINE] 37: Farquhar C, VanCott TC, MboriNgacha DA, Horani L, Bosire RK, Kreiss JK, Richardson BA, JohnStewart GC. Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk. J Infect Dis. 2020 Oct 15。 186(8):11736. PMID: 12355371 [PubMed indexed for MEDLINE] 38: Riddle TM, Schildmeyer NM, Phan C, Fichtenbaum CJ, Hui DY. The HIV protease inhibitor ritonavir increases lipoprotein production and has no effect on lipoprotein clearance in mice. J Lipid Res. 2020 Sep。 43(9):145863. PMID: 12235177 [PubMed in process] 39: Pajonk F, Himmelsbach J, Riess K, Sommer A, McBride WH. The human immunodeficiency virus (HIV)1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in nonHIVassociated human cancer cells. Cancer Res. 2020 Sep 15。 62(18):52305. PMID: 12234989 [PubMed indexed for MEDLINE] 40: Piliero PJ. Atazanavir: a novel HIV1 protease inhibitor. Expert Opin Investig Drugs. 2020 Sep。 11(9):1295301. Review. PMID: 12225250 [PubMed indexed for MEDLINE] 41: Jain AK, Venkataramanan R, Fridell JA, Gadomski M, Shaw LM, Ragni M, Korecka M, Fung J. Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report. Liver Transpl. 2020 Sep。 8(9):83840. PMID: 12202087 [PubMed indexed for MEDLINE] 42: Lewden C, Raffi F, Cuzin L, Cailleton V, Vilde JL, Chene G, Allavena C, Salamon R, Leport C. Factors associated with mortality in human immunodeficiency virus type 1infected adults initiating protease inhibitorcontaining therapy: role of education level and of early transaminase level elevation (APROCOANRS EP11 study). The Antiproteases Cohorte Agence Nationale de Recherches sur le SIDA EP 11 study. J Infect Dis. 2020 Sep 1。 186(5):7104. PMID: 12195361 [PubMed indexed for MEDLINE] 43: Lafeuillade A, Hittinger G, Chadapaud S, Maillefet S, Rieu A, Poggi C. The HYDILE trial: efficacy and tolerance of a quadruple bination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin2 in HIVinfected patients failing protease inhibitorbased binations. HIV Clin Trials. 2020 JulAug。 3(4):26371. PMID: 12187499 [PubMed indexed for MEDLINE] 44: Masquelier B, Breilh D, Neau D, LawsonAyayi S, Lavignolle V, Ragnaud JM, Dupon M, Morlat P, Dabis F, Fleury H. Human immunodeficiency virus type 1 genotypic and pharmacokiic determinants of the virological response to lopinavirritonavircontaining therapy in protease inhibitorexperienced patients. Antimicrob Agents Chemother. 2020 Sep。 46(9):292632. PMID: 12183249 [PubMed indexed for MEDLINE] 45: Faye A, Bertone C, Teglas JP, Chaix ML, Douard D, Firtion G, Thuret I, Dollfus C, Monpoux F, Floch C, Nicolas J, Vilmer E, Rouzioux C, Mayaux MJ, Blanche S. Early multitherapy including a protease inhibitor for human immunodeficiency virus type 1infected infants. Pediatr Infect Dis J. 2020 Jun。 21(6):51825. PMID: 12182375 [PubMed indexed for MEDLINE] 46: Hoffmann F, Funk M, Linde R, Notheis G, Petropoulou T, Eberle J, Gurtler L, Belohradsky BH, Wintergerst U. Effect of antiretroviral triple binations including the protease inhibitor nelfinavir in heavily pretreated children with HIV1 infection. Eur J Med Res. 2020 Jul 24。 7(7):3304. PMID: 12176683 [PubMed indexed for MEDLINE] 47: Gavin PJ, Yogev R. The role of protease inhibitor therapy in children with HIV infection. Paediatr Drugs. 2020。 4(9):581607. Review. PMID: 12175273 [PubMed indexed for MEDLINE] 48: Serone AP, Camargo SM, Schor N. The effect of an HIV1 viral protease inhibitor on staurosporineinduced apoptosis in immortalized mesangial cells. Sao Paulo Med J. 2020 May 2。 120(3):813. PMID: 12163898 [PubMed indexed for MEDLINE] 49: Hammer SM, Vaida F, Bent KK, Holohan MK, Sheiner L, Eron JJ, Wheat LJ, Mitsuyasu RT, Gulick RM, Valentine FT, Aberg JA, Rogers MD, Karol CN, Saah AJ, Lewis RH, Bessen LJ, Brosgart C, DeGruttola V, Mellors JW. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA. 2020 Jul 10。 288(2):16980. PMID: 12095381 [PubMed indexed for MEDLINE] 50: Dieleman JP, Sturkenboom MC, Jambroes M, Gyssens IC, Weverling GJ, ten Veen JH, Schrey G, Reiss P, Stricker BH. Risk factors for urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate: the ATHENA cohort. Arch Intern Med. 2020 Jul 8。 162(13):1493501. PMID: 12090886 [PubMed indexed for MEDLINE] 51: Franco A, Aprea L, Geraci A, Manzillo E, Pizzella T, Simioli F, Mongirulli A, Izzo CM. [Experience at a branch center of the National HIV Protease Inhibitor Registry] Infez Med. 2020 Sep。 9(3):1705. Italian. PMID: 12087219 [PubMed indexed for MEDLINE] 52: Weiss L, Burgard M, Cahen YD, Chaix ML, Laureillard D, Gilquin J, Piketty C, Viard JP, Kazatchkine MD, Girard PM, Rouzioux C. Immunological and virological features of HIVinfected patients with increasing CD4 cell numbers despite virological failure during protease inhibitorbased therapy. HIV Med. 2020 Jan。 3(1):1220. PMID: 12059946 [PubMed indexed for MEDLINE] 53: [No authors listed] [After 3 years no resistance development. Protease inhibitor with staying power] MMW Fortschr Med. 2020 Apr 9。 144 Suppl 1:567. German. No abstract available. PMID: 12043076 [PubMed indexed for MEDLINE] 54: Servais J, Hainaut M, Schmitz V, Maes P, Fransen K, Vaira D, Brichard B, Arendt V, Schneider F, Hemmer R, Schmit JC. Resistance testing in children changing human immunodeficiency virus t。